Study Shows Multiple Doses of Extracellular Vesicles May Reduce Lung Injury Risk in ICU Patients

A recent study conducted by Leksum LLC has revealed promising results regarding the use of extracellular vesicles (EVs) in mitigating lung injury risks for patients on mechanical ventilation (MV) in intensive care units (ICUs). The research indicates that multiple doses of EVs, derived from bone marrow mesenchymal stromal cells (BM-MSCs), can preserve diaphragm muscle fiber size and function, offering a potential solution to ventilator-induced diaphragm dysfunction (VIDD).

Initial findings show that after two doses of EVs, diaphragm muscle fiber cross-sectional area and specific force measurements were 93% and 94% of control values, respectively. This marks a significant improvement over untreated specimens, which showed measurements of 57% and 52% after five days. The study also noted stable hemodynamic parameters and reduced mucus accumulation, with lungs and diaphragm muscles appearing in good condition upon dissection.

This research builds on previous studies by Leksum's team, which have consistently demonstrated the efficacy of BM-MSC-derived EVs in addressing lung injury and muscle dysfunction associated with MV. The potential to mitigate these effects could not only improve patient outcomes but also reduce the substantial costs associated with the weaning process from MV, estimated at over $100 billion annually in the US and Europe.

Leksum LLC is preparing for Phase I trials in Europe to further investigate the therapeutic potential of EVs in treating muscle myopathies related to MV and other conditions such as sarcopenia and cancer cachexia. The findings underscore the importance of continued research into biologic therapies that could enhance the quality of life for millions of patients worldwide.